IP Library Granted Patent US 9,493,770
Granted Patent B2
US 9,493,770 · App. 14/071,618 · Granted Nov 15, 2016

Method for identifying antibiotic targets by complemented sequencing

Inventors: David Hugh Williams (Cambridge, GB); Arthur Keith Turner (Cambridge, GB)
Assignee: DISCUVA LIMITED
C12N15/1082C12N15/102C40B30/06G06F19/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,493,770
App. No.
14/071,618
Granted
Nov 15, 2016
Kind
B2
Abstract

Provided herein are methods, and related compositions for identifying a putative essential gene which serves as an antibiotic target in a bacterium, the method, in some embodiments, comprising (a) generating an antibiotic resistant mutant of the bacterium by a method comprising the step of selecting for growth in the presence of an antibiotic to produce an antibiotic resistant mutant clone (Ab R mutant); (b) transforming the Ab R mutant with one or more essential genes of the bacterium and a transposon which insertionally inactivates bacterial DNA to produce a pool of transposon mutants which are merodiploid for the one or more essential genes; (c) growing bacteria from the merodiploid pool in the presence of different amounts of the antibiotic to produce two or more test cultures; and (d) comparing the distribution of transposon insertions between the test cultures to identify a putative essential gene serving as a target of the antibiotic in the bacterium.

Claims (22)

1. A method for identifying a putative essential gene which serves as an antibiotic target in a bacterium, the method comprising the steps of:

(a) generating an antibiotic resistant mutant of said bacterium by a method comprising the step of selecting for growth in the presence of said antibiotic to produce an antibiotic resistant mutant clone (Ab R mutant);

(b) transforming the Ab R mutant with: (i) one or more wild-type copies of essential genes of said bacterium; and (ii) a transposon which insertionally inactivates bacterial DNA, to produce a pool of transposon mutants which are merodiploid for said one or more essential genes;

(c) growing bacteria from the merodiploid pool in the presence of different amounts of said antibiotic to produce two or more test cultures, wherein transposon insertions into an essential gene serving as an antibiotic target in the bacterial DNA are represented under non-selective conditions but not under selective conditions, and wherein one amount of said antibiotic is non-selective and another amount of said antibiotic is selective; and

(d) comparing the distribution of transposon insertions between test cultures to identify a putative essential gene serving as a target of said antibiotic in said bacterium.

2. The method of claim 1 wherein the merodiploid pool comprises at least 0.5×10 5 mutants.

3. The method of claim 1 wherein the merodiploid pool comprises at least 5×10 5 mutants.

4. The method of claim 1 wherein the merodiploid pool comprises at least 1×10 6 mutants.

5. The method of claim 1 wherein the merodiploid pool comprises 0.5×10 6 to 2 ×10 6 mutants.

6. The method of claim 5 wherein the merodiploid pool comprises about 1×10 6 mutants.

7. The method of claim 1 wherein transformation with the transposon in step (b) yields an insertion density of at least one transposon per 50 base pairs of bacterial DNA.

8. The method of claim 1 wherein transformation with the transposon in step (b) yields an insertion density of at least one transposon per 30 base pairs of bacterial DNA.

9. The method of claim 1 wherein transformation with the transposon in step (b) yields an insertion density of at least one transposon per 25 base pairs of bacterial DNA.

10. The method of claim 1 wherein transformation with the transposon in step (b) yields an insertion density of at least one transposon per 15 base pairs of bacterial DNA.

11. The method of claim 1 wherein transformation with the transposon in step (b) yields an insertion density of at least one transposon per 10 base pairs of bacterial DNA.

12. The method of claim 1 wherein the bacterial DNA of step (b) is genomic DNA.

13. The method of claim 1 wherein the bacterial DNA of step (b) is plasmid DNA or a mixture of genomic and plasmid DNA.

14. The method of claim 1 wherein in step (b) the Ab R mutant is first transformed with the one or more essential genes of said bacterium and then with the transposon.

15. The method of claim 14 wherein in step (b) the Ab R mutant is first transformed with an extrachromosomal element comprising: (i) one or more essential genes of said bacterium; and (ii) one or more transposon repeat sequences; and then transformed with a transposon delivery plasmid comprising: (i) a gene encoding a transposase; and (ii) invert repeat transposase recognition sites; wherein the one or more transposon repeat sequences of the extrachromosomal element confer transposon immunity against the transposon delivered by the transposon delivery plasmid.

16. The method of claim 2 wherein the merodiploid pool comprises at least 1×10 5 mutants.

17. The method of claim 15 , wherein the extrachromosomal element is a BAC or plasmid.

18. The method of claim 15 , wherein the Ab R mutant is transformed in step (ii) by conjugation with a donor bacterium.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2014
From: WILLIAMS, DAVID HUGH; TURNER, ARTHUR KEITH
To: DISCUVA LIMITED
Reel/Frame 032085/0290 →
Continuity (2)
Continuation PCTGB2012000403 · May 3, 2012
Related Publication 20140135234A1 · May 15, 2014